Anti-LRRC59 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The protein LRRC59 also known as Leucine-Rich Repeat-Containing Protein 59 is involved in several cellular processes. This protein has a molecular mass of approximately 40 kDa and is expressed in various tissues including the liver kidney and brain. LRRC59 contains multiple leucine-rich repeats which are structural motifs contributing to protein-protein interactions. These interactions are important for the protein's function within the cell.

Biological function summary

LRRC59 is involved in nuclear import pathways and acts as an anchor for certain proteins that need to be translocated into the nucleus. It interacts with the importin-family proteins to facilitate the transport of proteins with nuclear localization signals. LRRC59 works as a part of a larger protein complex which includes importin and nucleoporins to control transport into the nucleus. This positioning suggests that LRRC59 has an active role in regulating gene expression by controlling the nuclear entry of transcription factors and other nuclear proteins.

Pathways

LRRC59 plays a part in cellular transport and signaling pathways. It integrates into the nuclear transport pathway directly influencing gene expression by ensuring the proper nuclear import of signaling molecules. In particular it influences the well-known MAPK signaling pathway through interactions with other proteins like importin-β. These associations emphasize LRRC59’s role in maintaining cellular homeostasis and its potential impact on several signaling cascades.

Associated diseases and disorders

LRRC59 has been linked to specific cancers and certain neurodegenerative conditions. Abnormal expression of LRRC59 has been observed in some cancer types suggesting a role in tumor progression possibly through altered nuclear transport. Additionally LRRC59 is associated with Alzheimer's disease due to its interactions with proteins like tau which are involved in the pathological aggregation seen in this disorder. These connections highlight LRRC59 as a potential target for therapeutic interventions in these diseases.